Atıf İçin Kopyala
Icli F., Altundag K., Akbulut H., PAYDAŞ S., Basaran G. , Saip P., ...Daha Fazla
BREAST CANCER, cilt.22, ss.480-485, 2015 (SCI İndekslerine Giren Dergi)
Background Optimal duration of adjuvant trastuzumab in early breast cancer is an unresolved issue. In this observational study, we compared the outcome of 9 weeks and 1 year adjuvant trastuzumab in early breast cancer patients in Turkey.